Glaukos Corp Company Profile (NYSE:GKOS)

About Glaukos Corp (NYSE:GKOS)

Glaukos Corp logoGlaukos Corporation is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. It offers iStent, a micro-invasive glaucoma surgery (MIGS) device. The iStent is a micro-bypass stent inserted through the small corneal incision made during cataract surgery and placed into Schlemm's canal, a circular channel in the eye that collects aqueous humor and delivers it back into the bloodstream. It is developing three additional pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is a drug delivery system that is designed to be implanted in the eye to continuously deliver therapeutic levels of medication for extended periods of time to lower intraocular pressure in glaucoma patients.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Devices & Implants
  • Sub-Industry: N/A
  • Symbol: NYSE:GKOS
  • CUSIP: N/A
  • Web: www.glaukos.com/
Capitalization:
  • Market Cap: $1.42 billion
  • Outstanding Shares: 34,286,000
Average Prices:
  • 50 Day Moving Avg: $41.11
  • 200 Day Moving Avg: $43.09
  • 52 Week Range: $28.26 - $52.49
P/E:
  • Trailing P/E Ratio: 375.55
  • Foreward P/E Ratio: 76.50
  • P/E Growth: 1.60
Sales & Book Value:
  • Annual Revenue: $127.21 million
  • Price / Sales: 11.13
  • Book Value: $3.59 per share
  • Price / Book: 11.51
Profitability:
  • EBIDTA: $8.53 million
  • Net Margins: 2.45%
  • Return on Equity: 2.93%
  • Return on Assets: 2.59%
Debt:
  • Current Ratio: 8.45%
  • Quick Ratio: 7.94%
Misc:
  • Average Volume: 592,721 shs.
  • Beta: 1.33
  • Short Ratio: 8.2
 
Frequently Asked Questions for Glaukos Corp (NYSE:GKOS)

What is Glaukos Corp's stock symbol?

Glaukos Corp trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos Corp's earnings last quarter?

Glaukos Corp (NYSE:GKOS) announced its quarterly earnings results on Wednesday, March, 1st. The company reported $0.00 EPS for the quarter, beating the consensus estimate of $0.00 by $0.00. The company had revenue of $33.17 million for the quarter, compared to analyst estimates of $29.49 million. Glaukos Corp had a net margin of 2.45% and a return on equity of 2.93%. Glaukos Corp's revenue was up 63.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.07) earnings per share. View Glaukos Corp's Earnings History.

Where is Glaukos Corp's stock going? Where will Glaukos Corp's stock price be in 2017?

7 equities research analysts have issued 1 year price targets for Glaukos Corp's shares. Their forecasts range from $41.00 to $55.00. On average, they anticipate Glaukos Corp's stock price to reach $49.20 in the next year. View Analyst Ratings for Glaukos Corp.

What are analysts saying about Glaukos Corp stock?

Here are some recent quotes from research analysts about Glaukos Corp stock:

  • 1. According to Zacks Investment Research, "Glaukos Corporation is an ophthalmic medical technology company. The Company develops, manufactures and markets medical devices for the treatment of glaucoma. Its product pipeline consists of iStent Inject, the iStent Supra and iDose. The company operates primarily in United States, Germany, Europe, the Asia Pacific, Canada and internationally. Glaukos Corporation is headquartered in Laguna Hills, California. " (7/21/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are reiterating our Overweight rating on GKOS and raising our price target to $54 from $45, following what we view as impressive 4Q16 results and strong revenue guidance for 2017. Yesterday after the close, Glaukos reported 4Q16 revenues of $33.2 million, beating our revenue estimate of $30.0 million. We note that $2 million of the growth was associated with advanced sales to ASC customers ahead of increased reimbursement changes. Management provided initial 2017 sales guidance of $160-165 million, above our previous estimate of $140 million. We have updated our model to reflect the better-than-anticipated guidance and are extending our NPV out by one year, which is reflected in our increased 12-month price target." (3/2/2017)
  • 3. Stifel Nicolaus analysts commented, "Glaukos' stock has considerably outperformed the market YTD (+29% relative to the S&P). We attribute the strong performance to ongoing positive investor sentiment as well as a better understanding of the pricing power that the company possesses in 2017 due to the favorable Ambulatory Surgical Center (ASC) reimbursement decision that took hold at the beginning of the year. While Glaukos does not plan to provide ASP details, our late January diligence among a small number of iStent physicians unveiled that Glaukos is in the midst of implementing a significant price increase (~40%) among iStent cases performed at the ASC. A price increase of this magnitude implies upside to the Street's current 2017 revenue estimate of $147.5MM (we are at $151.4MME), and our January report laid out a case where 2017 revenue could total $180MM+. As investors have better understood the power of price over the past few weeks, we believe the bar has been raised into the company's 2017 guidance, which will be provided on Wednesday (AMC). In this report, we take a near-term look at what different 2017 revenue guidance levels imply for 2017 iStent volumes based on our ASP diligence. We also take a longer-term look at Glaukos' future earnings power, which we view as significant, and believe will become more evident in 2H17 / 1H18. Simply put, we can see 2019 adjusted EBITDA per share (which we use as a proxy for cash EPS) of $2.23 to $3.33, which does not include future pipeline products such as iDose, or the significant market opportunity associated with the stand-alone Glaucoma market." (2/28/2017)

Who are some of Glaukos Corp's key competitors?

Who are Glaukos Corp's key executives?

Glaukos Corp's management team includes the folowing people:

  • William J. Link Ph.D., Independent Chairman of the Board
  • Thomas William Burns, President, Chief Executive Officer and Director
  • Joseph E. Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development
  • Chris M. Calcaterra, Chief Commercial Officer and Chief Operating Officer
  • L. Jay Katz, Chief Medical Officer
  • Mark J. Foley, Independent Director
  • David F. Hoffmeister, Independent Director
  • Gilbert Kliman M.D., Independent Director
  • Jonathan Todd Silverstein J.D., Independent Director
  • Marc A. Stapley, Independent Director

When did Glaukos Corp IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who owns Glaukos Corp stock?

Glaukos Corp's stock is owned by a number of of retail and institutional investors. Top institutional investors include InterWest Venture Management Co (2.97%), Peregrine Capital Management LLC (0.96%), Handelsbanken Fonder AB (0.41%), Handelsinvest Investeringsforvaltning (0.15%), Bank of Montreal Can (0.05%) and Fox Run Management L.L.C. (0.04%). Company insiders that own Glaukos Corp stock include Aimee S Weisner, Chris M Calcaterra, Jonathan Silverstein, Montreux Equity Partners Iv Lp, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Institutional Ownership Trends for Glaukos Corp.

Who sold Glaukos Corp stock? Who is selling Glaukos Corp stock?

Glaukos Corp's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can and Handelsbanken Fonder AB. Company insiders that have sold Glaukos Corp stock in the last year include Chris M Calcaterra, Jonathan Silverstein, Orbimed Advisors Llc, Richard L Harrison, Thomas William Burns and William J Phd Link. View Insider Buying and Selling for Glaukos Corp.

Who bought Glaukos Corp stock? Who is buying Glaukos Corp stock?

Glaukos Corp's stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Handelsinvest Investeringsforvaltning and Fox Run Management L.L.C.. Company insiders that have bought Glaukos Corp stock in the last two years include Aimee S Weisner and Richard L Harrison. View Insider Buying and Selling for Glaukos Corp.

How do I buy Glaukos Corp stock?

Shares of Glaukos Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Glaukos Corp's stock price today?

One share of Glaukos Corp stock can currently be purchased for approximately $41.31.


MarketBeat Community Rating for Glaukos Corp (NYSE GKOS)
Community Ranking:  3.6 out of 5 (  )
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  198
MarketBeat's community ratings are surveys of what our community members think about Glaukos Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Glaukos Corp (NYSE:GKOS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $49.20 (19.10% upside)

Analysts' Ratings History for Glaukos Corp (NYSE:GKOS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/8/2017StephensUpgradeEqual Weight -> OverweightLowView Rating Details
5/4/2017Cantor FitzgeraldReiterated RatingOverweight$54.00HighView Rating Details
4/11/2017BMO Capital MarketsReiterated RatingBuy$54.00MediumView Rating Details
2/28/2017Stifel NicolausBoost Price TargetPositive$45.00 -> $55.00N/AView Rating Details
10/27/2016Wells Fargo & CompanyInitiated CoverageOutperformN/AView Rating Details
8/2/2016Roth CapitalBoost Price TargetBuy$36.50 -> $41.00N/AView Rating Details
8/2/2016Piper Jaffray CompaniesBoost Price Target$42.00N/AView Rating Details
3/2/2016J P Morgan Chase & CoLower Price TargetOverweight$32.00 -> $28.00N/AView Rating Details
11/19/2015William BlairReiterated RatingOutperformN/AView Rating Details
8/27/2015Goldman Sachs Group, Inc. (The)Lower Price Target$33.00 -> $32.00N/AView Rating Details
(Data available from 7/24/2015 forward)

Earnings

Earnings History for Glaukos Corp (NYSE:GKOS)
Earnings by Quarter for Glaukos Corp (NYSE:GKOS)
Earnings History by Quarter for Glaukos Corp (NYSE GKOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2017Q416$0.00$0.00$29.49 million$33.17 millionViewListenView Earnings Details
11/10/2016Q316($0.01)$0.03$27.21 million$29.60 millionViewN/AView Earnings Details
8/1/2016Q216($0.04)$0.06$24.45 million$28.60 millionViewN/AView Earnings Details
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Glaukos Corp (NYSE:GKOS)
Current Year EPS Consensus Estimate: $0.21 EPS
Next Year EPS Consensus Estimate: $0.54 EPS

Dividends

Dividend History for Glaukos Corp (NYSE:GKOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Glaukos Corp (NYSE:GKOS)
Insider Ownership Percentage: 16.40%
Institutional Ownership Percentage: 88.98%
Insider Trades by Quarter for Glaukos Corp (NYSE:GKOS)
Institutional Ownership by Quarter for Glaukos Corp (NYSE:GKOS)
Insider Trades by Quarter for Glaukos Corp (NYSE:GKOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/14/2017Orbimed Advisors LlcDirectorSell382,538$45.33$17,340,447.54View SEC Filing  
2/2/2017Thomas William BurnsCEOSell50,000$42.58$2,129,000.00View SEC Filing  
1/13/2017Chris M CalcaterraInsiderSell18,136$40.01$725,621.36View SEC Filing  
1/13/2017Richard L HarrisonCFOSell20,634$40.00$825,360.00View SEC Filing  
1/9/2017Chris M CalcaterraInsiderSell20,000$38.02$760,400.00View SEC Filing  
1/9/2017Thomas William BurnsCEOSell40,000$37.60$1,504,000.00View SEC Filing  
1/6/2017Richard L HarrisonCFOSell20,634$35.58$734,157.72View SEC Filing  
11/17/2016William J Phd LinkDirectorSell30,000$33.78$1,013,400.00View SEC Filing  
11/15/2016Thomas William BurnsCEOSell200,120$33.68$6,740,041.60View SEC Filing  
10/24/2016Chris M CalcaterraInsiderSell20,000$36.01$720,200.00View SEC Filing  
10/20/2016Chris M CalcaterraInsiderSell40,000$34.76$1,390,400.00View SEC Filing  
8/12/2016Jonathan SilversteinDirectorSell292,938$33.69$9,869,081.22View SEC Filing  
8/3/2016Orbimed Advisors LlcDirectorSell425,000$30.59$13,000,750.00View SEC Filing  
7/27/2016Richard L HarrisonCFOSell10,000$35.01$350,100.00View SEC Filing  
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.78View SEC Filing  
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.00View SEC Filing  
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.00View SEC Filing  
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.00View SEC Filing  
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44View SEC Filing  
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.48View SEC Filing  
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.00View SEC Filing  
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.00View SEC Filing  
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.00View SEC Filing  
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40View SEC Filing  
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.00View SEC Filing  
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.00View SEC Filing  
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.40View SEC Filing  
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Glaukos Corp (NYSE:GKOS)
Latest Headlines for Glaukos Corp (NYSE:GKOS)
Source:
DateHeadline
finance.yahoo.com logoETFs with exposure to Glaukos Corp. : July 24, 2017
finance.yahoo.com - July 24 at 8:43 PM
nasdaq.com logoGlaukos (GKOS) Shares Cross Below 200 DMA - Nasdaq
www.nasdaq.com - July 22 at 12:28 AM
americanbankingnews.com logoGlaukos Corporation (GKOS) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - July 21 at 9:56 PM
businesswire.com logoGlaukos Corporation to Release Second Quarter 2017 Financial Results after Market Close on August 2
www.businesswire.com - July 19 at 7:43 PM
finance.yahoo.com logoGlaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : July 19, 2017
finance.yahoo.com - July 19 at 7:43 PM
americanbankingnews.com logoGlaukos Corporation (GKOS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 16 at 12:58 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Glaukos Corporation (GKOS) Will Post Quarterly Sales of $39.88 Million
www.americanbankingnews.com - July 14 at 4:24 PM
americanbankingnews.com logo Brokerages Expect Glaukos Corporation (GKOS) to Post $0.06 EPS
www.americanbankingnews.com - July 12 at 7:34 AM
finance.yahoo.com logoETFs with exposure to Glaukos Corp. : July 11, 2017
finance.yahoo.com - July 11 at 8:14 PM
americanbankingnews.com logoGlaukos Corporation (GKOS) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - July 10 at 4:52 PM
finance.yahoo.com logoGlaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : July 6, 2017
finance.yahoo.com - July 6 at 8:58 PM
finance.yahoo.com logoETFs with exposure to Glaukos Corp. : June 30, 2017
finance.yahoo.com - June 30 at 7:21 PM
americanbankingnews.com logoGlaukos Corporation (GKOS) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - June 24 at 6:44 PM
finance.yahoo.com logoGlaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : June 22, 2017
finance.yahoo.com - June 22 at 9:25 AM
streetinsider.com logoGlaukos Corporation (GKOS) Announces Study of 53 Open-angle ... - StreetInsider.com
www.streetinsider.com - June 21 at 7:06 PM
finance.yahoo.com logoCombining Implantation of Glaukos iStent inject® Trabecular Micro-Bypass with Topical Travoprost Provides Sustained IOP Reduction and Favorable Safety Profile, According to New Study
finance.yahoo.com - June 21 at 7:06 PM
finance.yahoo.com logoETFs with exposure to Glaukos Corp. : June 19, 2017
finance.yahoo.com - June 19 at 4:20 PM
americanbankingnews.com logoZacks: Analysts Expect Glaukos Corporation (GKOS) Will Announce Quarterly Sales of $39.88 Million
www.americanbankingnews.com - June 18 at 10:26 AM
americanbankingnews.com logoAnalyzing HeartWare International (HTWR) & Glaukos Corporation (GKOS)
www.americanbankingnews.com - June 17 at 6:22 PM
finance.yahoo.com logoGlaukos Corp. :GKOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017
finance.yahoo.com - June 16 at 6:12 PM
americanbankingnews.com logo$0.06 EPS Expected for Glaukos Corporation (GKOS) This Quarter
www.americanbankingnews.com - June 16 at 8:24 AM
americanbankingnews.com logoGlaukos Corporation (GKOS) & HeartWare International (HTWR) Head-To-Head Analysis
www.americanbankingnews.com - June 15 at 2:08 PM
americanbankingnews.com logoGlaukos Corporation (GKOS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 13 at 5:04 PM
finance.yahoo.com logoGlaukos Announces Participation in William Blair Growth Stock Conference
finance.yahoo.com - May 30 at 5:21 PM
streetinsider.com logoGlaukos Corporation (GKOS) Says Study Reveals Potential Cost Efficiency of Using Two iStent Trabecular Micro ... - StreetInsider.com
www.streetinsider.com - May 24 at 11:57 AM
streetinsider.com logoGlaukos Corporation (GKOS) Says Study Reveals Potential Cost Efficiency of Using Two iStent Trabecular Micro-Bypass Stents
www.streetinsider.com - May 23 at 11:46 AM
finance.yahoo.com logoStudy Reveals Potential Cost Efficiency of Using Two Glaukos iStent® Trabecular Micro-Bypass Stents to Treat Elevated IOP in Glaucoma Patients
finance.yahoo.com - May 22 at 5:01 PM
americanbankingnews.com logoGlaukos Corp (GKOS) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 5:08 PM
nasdaq.com logoGKOS Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - May 17 at 10:26 PM
americanbankingnews.com logoGlaukos Corp (GKOS) Lifted to Overweight at Stephens
www.americanbankingnews.com - May 8 at 1:00 PM
americanbankingnews.com logoGlaukos Corp (GKOS) Downgraded by TheStreet
www.americanbankingnews.com - May 6 at 11:52 PM
americanbankingnews.com logoGlaukos Corp (GKOS) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - May 4 at 11:52 PM
streetinsider.com logoGlaukos Corporation (GKOS) Tops Q1 EPS by 4c; Raises Outlook
www.streetinsider.com - May 4 at 12:07 PM
finance.yahoo.com logoEdited Transcript of GKOS earnings conference call or presentation 3-May-17 8:30pm GMT
finance.yahoo.com - May 4 at 12:07 PM
americanbankingnews.com logoZacks: Analysts Anticipate Glaukos Corp (GKOS) Will Announce Quarterly Sales of $32.66 Million
www.americanbankingnews.com - May 4 at 1:05 AM
americanbankingnews.com logo Analysts Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - May 4 at 1:05 AM
seekingalpha.com logoGlaukos' (GKOS) CEO Tom Burns on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 10:15 PM
marketbeat.com logoGlaukos beats Street 1Q forecasts
marketbeat.com - May 3 at 7:37 PM
finance.yahoo.com logoGlaukos Corporation Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 3 at 5:13 PM
finance.yahoo.com logoGlaukos Completes Patient Enrollment in Phase II Clinical Trial for iDose™ Travoprost Intraocular Implant in Glaucoma Patients
finance.yahoo.com - May 3 at 9:25 AM
americanbankingnews.com logoGlaukos Corp (GKOS) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - May 3 at 1:10 AM
americanbankingnews.com logoGlaukos Corp (GKOS) Getting Somewhat Positive News Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 6:34 PM
finance.yahoo.com logoGlaukos Announces Participation in Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 2 at 2:01 PM
finance.yahoo.com logoGlaukos Corp. – Value Analysis (NYSE:GKOS) : May 1, 2017
finance.yahoo.com - May 1 at 5:13 PM
finance.yahoo.com logoSeveral Surgeon Presentations to Include Glaukos Technologies at 2017 American Society of Cataract and Refractive Surgery
finance.yahoo.com - May 1 at 12:07 PM
americanbankingnews.com logo Brokerages Expect Glaukos Corp (GKOS) Will Post Quarterly Sales of $32.66 Million
www.americanbankingnews.com - April 30 at 9:36 AM
americanbankingnews.com logoGlaukos Corp (GKOS) Receives Coverage Optimism Rating of 0.10
www.americanbankingnews.com - April 29 at 4:19 PM
finance.yahoo.com logoGlaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : April 28, 2017
finance.yahoo.com - April 28 at 10:40 AM
americanbankingnews.com logoZacks: Analysts Expect Glaukos Corp (GKOS) Will Post Earnings of -$0.02 Per Share
www.americanbankingnews.com - April 28 at 9:08 AM
americanbankingnews.com logoGlaukos Corp (GKOS) Getting Somewhat Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 25 at 8:56 PM

Social

Chart

Glaukos Corp (GKOS) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by MarketBeat.com Staff